CBIH · CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
Cannabis Bioscience International Holdings Inc (CBIH)
What's happening
- CBIH is up 0.00% today, trading at $0.00. — Live quote
- It's trading within 3% of its 52-week low ($0.00). (Finnhub fundamentals)
- Reports earnings on 2026-09-21, 18 days away. (Finnhub earnings calendar)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Valuation Measures & Ratios
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-07-15. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Signals describe daily price patterns—not the company’s value and not a recommendation to buy or sell. Read several together; no single indicator predicts what happens next. “Overbought” and “oversold” are conditions, not promises of a reversal.
Indicators None active
Free IEX historical data only goes back to ~2021 — 5Y/Full show whatever's actually available, not a promise of that much history. Indicators are computed client-side from these same price bars; earnings markers ("E") come from Finnhub's free tier (~last 4 quarters + next upcoming) — older quarters aren't available. The move-highlight dots are a heuristic (|% change| vs rolling volatility) with a best-effort headline lookup, not a claim of causation.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 10-Q, filed 2026-04-16; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -24.9% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -416.8%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CBIH
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Feb '26 | Nov '25 | Aug '25 | Feb '25 | Nov '24 | Aug '24 | Feb '24 | Nov '23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.2K | $53.3K | $24.2K | $14.9K | $74.2K | $178.9K | $36.4K | $63.7K |
| Gross profit | $8.2K | $42.8K | $16.1K | -$4.5K | $66.4K | $170.5K | $24.6K | $48.7K |
| Operating income | -$93.3K | -$95.9K | -$74.8K | -$129.2K | -$59.6K | -$97.6K | -$160.0K | -$94.5K |
| Net income | -$103.9K | -$117.0K | -$82.6K | -$181.2K | -$79.5K | -$76.3K | -$209.2K | -$124.4K |
| EPS (diluted) | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 |
| EPS (basic) | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 |
| Operating margin | -$832 | -$180 | -$309 | -$866 | -$80 | -$55 | -$439 | -$148 |
| Net margin | -$928 | -$220 | -$342 | -$1.2K | -$107 | -$43 | -$575 | -$195 |
Balance sheet
| Line item | Feb '26 | Nov '25 | Aug '25 | May '25 | Feb '25 | Nov '24 | Aug '24 | May '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.5K | $22.1K | $18.9K | $31.9K | — | — | $46.3K | $57.2K |
| Total liabilities | $1.5M | $1.4M | $1.3M | $1.2M | — | — | $1.1M | $1.1M |
| Stockholders' equity | -$1.5M | -$1.4M | -$1.2M | -$1.2M | -$1.2M | -$1.1M | -$1.1M | -$1.1M |
| Total current assets | $1.5K | $22.1K | $18.9K | $29.1K | — | — | $18.7K | $21.5K |
| Total current liabilities | $1.2M | $1.1M | $1.0M | $946.0K | — | — | $852.1K | $881.9K |
| Cash & equivalents | — | — | — | — | — | — | — | — |
| Accounts receivable | $1.3K | $21.8K | $9.0K | $6.4K | — | — | $17.2K | $20.1K |
| Inventory | — | — | — | — | — | — | — | — |
| Other current assets | $188 | $188 | $598 | $598 | — | — | $598 | $598 |
| Property, plant & equipment | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | — | — | — | — | — | — | — | $0 |
| Short-term debt | $111.7K | $111.7K | $111.7K | $111.7K | — | — | $112.6K | $136.2K |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Long-term debt | $249.5K | $249.5K | $249.5K | $249.5K | — | — | $249.5K | $249.4K |
| Common stock & paid-in capital | $0 | $0 | $0 | $0 | — | — | $0 | $0 |
| Retained earnings | -$6.2M | -$6.1M | -$6.0M | -$5.9M | — | — | -$5.4M | -$5.3M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Feb '26 | Nov '25 | Aug '25 | May '25 | Feb '25 | Nov '24 | Aug '24 | May '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.6K | -$5.5K | -$103.7K | -$144.3K | -$82.8K | -$72.1K | -$30.4K | -$174.4K |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | $110.9K | — | — | $156.7K | $154.5K | — | $30.6K | $174.4K |
| Capital expenditures | — | — | — | — | — | — | — | — |
| Share-based compensation | — | — | — | — | — | — | — | $0 |
| Change in accounts receivable | -$20.5K | $12.8K | $2.6K | $3.7K | -$11.2K | -$3.4K | -$3.0K | $3.1K |
| Change in inventory | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
Income statement
| Line item | May '25 | May '24 | May '23 |
|---|---|---|---|
| Revenue | $303.0K | $248.8K | $316.8K |
| Gross profit | $262.9K | $203.2K | $223.4K |
| Operating income | -$421.4K | -$486.1K | -$983.4K |
| Net income | -$548.8K | -$651.3K | -$1.0M |
| EPS (diluted) | $-0.00 | $-0.00 | $-0.00 |
| EPS (basic) | $-0.00 | $-0.00 | $-0.00 |
| Operating margin | -$139 | -$195 | -$310 |
| Net margin | -$181 | -$262 | -$326 |
Balance sheet
| Line item | May '25 | May '24 | May '23 | May '22 |
|---|---|---|---|---|
| Total assets | $31.9K | $57.2K | $43.4K | — |
| Total liabilities | $1.2M | $1.1M | $635.0K | — |
| Stockholders' equity | -$1.2M | -$1.1M | -$591.7K | -$361.1K |
| Total current assets | $29.1K | $21.5K | $19.5K | — |
| Total current liabilities | $946.0K | $881.9K | $385.5K | — |
| Accounts receivable | $6.4K | $20.1K | $10.0K | — |
| Other current assets | $598 | $598 | $598 | — |
| Deferred revenue (current) | — | $0 | $28.6K | — |
| Short-term debt | $111.7K | $136.2K | $121.4K | — |
| Long-term debt | $249.5K | $249.4K | $249.5K | — |
| Common stock & paid-in capital | $0 | $0 | $0 | — |
| Retained earnings | -$5.9M | -$5.3M | -$4.7M | — |
Cash flow
| Line item | May '25 | May '24 | May '23 |
|---|---|---|---|
| Operating cash flow | -$329.6K | -$479.4K | -$898.4K |
| Financing cash flow | $341.8K | $471.2K | $875.3K |
| Share-based compensation | — | $0 | $12.0K |
| Change in accounts receivable | -$13.8K | $10.2K | $4.9K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CBIH as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-03 11:52 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-04-16 | 10-Q | 2026-02-28 | View on SEC.gov → |
| 2026-02-19 | 10-Q | 2025-11-30 | View on SEC.gov → |
| 2025-10-22 | 10-Q | 2025-08-31 | View on SEC.gov → |
| 2025-09-22 | 10-K | 2025-05-31 | View on SEC.gov → |
| 2025-04-22 | 10-Q | 2025-02-28 | View on SEC.gov → |
| 2025-01-22 | 8-K | 2024-12-27 | View on SEC.gov → |
| 2025-01-21 | 10-Q | 2024-11-30 | View on SEC.gov → |
| 2024-11-26 | 8-K | 2024-11-22 | View on SEC.gov → |
| 2024-10-21 | 10-Q | 2024-08-31 | View on SEC.gov → |
| 2024-09-16 | 10-K | 2024-05-31 | View on SEC.gov → |
| 2024-08-22 | 8-K | 2024-08-11 | View on SEC.gov → |
| 2024-04-22 | 10-Q | 2024-02-29 | View on SEC.gov → |
Recent news
Headlines about CBIH (CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.). Links open the publisher — we don’t host full articles.
-
CBIH Unveils Cannabinoid-Based Intranasal Platform for Alzheimer's Research
Yahoo Finance · 2026-07-20 -
Years of Preparation. One Regulatory Approval. Commercial Launch Begins: CBIH Receives Texas License for Consumable Hemp Products
Yahoo Finance · 2026-07-15 -
CBIH Announces Recognition Initiative Funded Through CEO's Personal Share Holdings
Yahoo Finance · 2026-07-06 -
Cannabis Bioscience International Holdings Opens New Revenue Pathway with First VitaCookies Licensing Agreement
Yahoo Finance · 2026-06-22 -
CBIH Announces Patent-Related Scientific Framework for PTSD-Focused Cannabinoid and Psilocybin Research
Yahoo Finance · 2026-06-15 -
China Infrastructure Construction CEO to return 500M shares
Seeking Alpha · 2022-03-28
No headlines in this category right now — try “All”.